top of page

®

Foveal LLP Independent Investment Research Foveal Research

Independent Investment Research

therapeutic topics_

Focus Research

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

WCLC: Hold you HARMONis: Keytruda safe from Summit

WCLC: Hold you HARMONis: Keytruda safe from Summit

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

MRNA/MRK: ASCO cancer vaccine data does not address pre-treatment imbalances that may be driving result

MRNA/MRK: ASCO cancer vaccine data does not address pre-treatment imbalances that may be driving result

ROG/SRPT: Duchenne EMBARK likely enought to lessen age restrictions

ROG/SRPT: Duchenne EMBARK likely enought to lessen age restrictions

Recent Research

NOVN: NATALEE's Kisqali of Life

Jun 6, 2023

NOVN: NATALEE's Kisqali of Life

As we highlighted in our February 23, 2020 report “Kisqali’s kiss of life“, NOVN's NATALEE trial of Kisqali demonstrated the broadest...

NOVN Kisqali incumbent competitor Ibrance shows no OS benefit

Jun 21, 2022

NOVN Kisqali incumbent competitor Ibrance shows no OS benefit

ASCO2022 saw the eventual presentation of Pfizer's PALOMA-2 study, where, as we highlighted in our February 2020 Foveal report NOVN...

PD1 Combos at ESMO good for AZN and BMY not for MRK and ROG

Oct 17, 2016

PD1 Combos at ESMO good for AZN and BMY not for MRK and ROG

Chemo combos continue to look equivocal, while IO combos remain durable as MYSTIC’s shadow clears New ESMO lung cancer data bodes well...

Unravelling the MYSTICal

Oct 13, 2016

Unravelling the MYSTICal

Astra's underappreciated oncology pipeline stalking the market We initiate on AstraZeneca with an overweight rating and a Target Price of...

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough

Dec 11, 2024

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

ADC: AZN Dato overall survival misses underscores our long held concerns for ADC's in 1L Lung

Oct 3, 2024

WCLC: Hold you HARMONis: Keytruda safe from Summit

Sep 22, 2024

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

ADCs @ ASCO: concerns over Dato-DXd in 1L Lung; GILD 2L OS as bad as AZN; SKB high ORR in unusual trial

Jul 1, 2024

MRNA/MRK: ASCO cancer vaccine data does not address pre-treatment imbalances that may be driving result

Jun 18, 2024

ROG/SRPT: Duchenne EMBARK likely enought to lessen age restrictions

May 29, 2024

AZN/ROG: Roche/AZN: SERDs restrict or fail

Apr 23, 2024

CYTK/BMY: aficamten approvable, but may not be better than BMY rival Camzyos

CYTK/BMY: aficamten approvable, but may not be better than BMY rival Camzyos

Feb 29, 2024

MRK: One big hit amongst smaller approvable assets

MRK: One big hit amongst smaller approvable assets

Feb 5, 2024

BMY/JNJ/BAYN: Bayer AF failure does not reduce chances for Factor XI in stroke

Nov 20, 2023

Archive

Search By Tags

Follow Us

Bloomberg: FOVL <go>

ThomsonReuters

FactSet

Captial IQ

bottom of page